CIK 0001601830 · Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464099738
- Phone
- (385) 269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-18 | Michor Franziska Director | Grant or award | +22,016 | 127,053 | ||
| 2025-06-18 | Michor Franziska Director | Grant or award · Stock Option (Right to Buy) | +44,031 | 44,031 | ||
| 2025-06-18 | HERSHBERG ROBERT Director | Grant or award | +22,016 | 73,732 | ||
| 2025-06-18 | HERSHBERG ROBERT Director | Grant or award · Stock Option (Right to Buy) | +44,031 | 44,031 | ||
| 2025-06-18 | Dar Zavain Director | Grant or award | +22,016 | 132,893 | ||
| 2025-06-18 | Dar Zavain Director | Grant or award · Stock Option (Right to Buy) | +44,031 | 44,031 | ||
| 2025-06-18 | Bumpus Namandje Director | Grant or award | +11,008 | 47,557 | ||
| 2025-06-18 | Bumpus Namandje Director | Grant or award · Stock Option (Right to Buy) | +22,016 | 22,016 | ||
| 2025-06-18 | Li Dean Y Director | Grant or award | +22,016 | 1,234,618 | ||
| 2025-06-18 | Li Dean Y Director | Grant or award · Stock Option (Right to Buy) | +44,031 | 44,031 | ||
| 2025-06-18 | Sun Elaine D Director | Grant or award | +11,008 | 47,557 | ||
| 2025-06-18 | Sun Elaine D Director | Grant or award · Stock Option (Right to Buy) | +22,016 | 22,016 | ||
| 2025-06-16 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −7,057 | $4.92 | $35K | 823,134 |
| 2025-05-15 | Khan Najat Chief R&D Commercial Officer | Shares withheld for taxes | −3,796 | $4.25 | $16K | 708,585 |
| 2025-05-15 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −11,908 | $4.25 | $51K | 830,191 |
| 2025-05-15 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −36,197 | $4.25 | $154K | 1,081,253 |
| 2025-04-01 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −26,571 | $5.10 | $135K | 842,099 |
| 2025-04-01 | Li Dean Y Director | Grant or award | +2,268 | 79,618 | ||
| 2025-04-01 | Dar Zavain Director | Grant or award | +2,745 | 110,877 |
Page 9 of 9 · 179 trades